New opportunities to optimize antithrombotic therapy for secondary stroke prevention

被引:4
|
作者
Kim, Anthony S. [1 ]
Easton, J. Donald [1 ]
机构
[1] UCSF, Dept Neurol, San Francisco, CA USA
关键词
Stroke prevention; secondary stroke prevention; antithrombotic; antiplatelet; clopidogrel; ticagrelor; aspirin; transient ischemic attack; MINOR STROKE; ASPIRIN; CLOPIDOGREL;
D O I
10.1177/1747493019828548
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke symptoms can be unsettling, even when symptoms resolve, but focusing on stroke prevention can be empowering provided that effective interventions for appropriate patient populations are available. Current options include interventions for symptomatic carotid artery stenosis, anticoagulation for atrial fibrillation, high-dose statins, new oral anticoagulants, new developments in atrial fibrillation detection, and new therapeutics are in development. For antiplatelet therapy, aspirin monotherapy is effective but dual antiplatelet therapy with the combination of aspirin and clopidogrel increases hemorrhage risks over the long term that outweigh potential benefits. In the short term though, both the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials have shown a benefit of short-term dual-antiplatelet therapy, though the increased major hemorrhage risk seen in POINT could justify applying dual-antiplatelet therapy to just the first 21 days. Furthermore, since clopidogrel is a prodrug that must be metabolized to have antiplatelet activity, it is not surprising that the treatment effect in CHANCE was limited to patients who were not carriers of loss-of-function alleles for clopidogrel metabolism. Ticagrelor, an antiplatelet agent which failed to meet its primary endpoint as monotherapy compared to aspirin in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial, is currently being tested as combination therapy with aspirin compared to aspirin alone in Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES). These developments along with improvements to the infrastructure to perform rapid evaluations and to apply intensive secondary stroke prevention interventions hold continued promise for the future.
引用
收藏
页码:220 / 222
页数:3
相关论文
共 50 条
  • [21] Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure
    Lusk, Jay B.
    Xu, Haolin
    Peterson, Eric D.
    Bhatt, Deepak L.
    Fonarow, Gregg C.
    Smith, Eric E.
    Matsouaka, Roland
    Schwamm, Lee H.
    Xian, Ying
    STROKE, 2021, 52 (12) : E777 - E781
  • [22] The Role of Antithrombotics in Secondary Stroke Prevention
    Lazzaro, Marc A.
    Malhotra, Konark
    Mohammad, Yousef M.
    SEMINARS IN NEUROLOGY, 2010, 30 (05) : 492 - 500
  • [23] The cause of stroke matters for secondary prevention
    Diener, Hans-Christoph
    LANCET NEUROLOGY, 2017, 16 (04) : 256 - 257
  • [24] A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke
    Marsden, Katelyn
    Mak, Hannah Y.
    Crooks, C. Patrick
    Pankaj, Preethy
    Thuhien Nguyen
    Tirschwell, David
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (10)
  • [25] Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines
    Shah, Jay
    Liu, Shimeng
    Yu, Wengui
    STROKE AND VASCULAR NEUROLOGY, 2022, 7 (05) : 406 - 414
  • [26] Antiplatelet therapy in secondary ischemic stroke prevention - a short review
    Florescu, Cristina
    Mustafa, Edme Roxana
    Tartea, Elena-Anca
    Florescu, Diana-Ruxandra
    Albu, Valeria-Carmen
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2019, 60 (02) : 383 - 387
  • [27] Antiplatelet Therapy for Secondary Prevention in Stroke - Making the Right Choice
    Ling, Geoffrey
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (02) : 225 - 237
  • [28] Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials
    Tornyos, Daniel
    Komocsi, Andras
    Balint, Alexandra
    Kupo, Peter
    El Abdallaoui, Oumaima El Alaoui
    Szapary, Laszlo
    Szapary, Laszlo Botond
    PLOS ONE, 2022, 17 (08):
  • [29] Controversies in antiplatelet therapy in the secondary prevention of stroke
    Adamek, T.
    EUROPEAN GERIATRIC MEDICINE, 2016, 7 (01) : 65 - 69
  • [30] STROKE Secondary stroke prevention-personalized antiplatelet therapy
    Tanne, David
    NATURE REVIEWS NEUROLOGY, 2012, 8 (10) : 536 - 537